BRNS
NASDAQBarinthus Biotherapeutics plc
News25/Ratings0
News · 26 weeks34-95%
2026-04-192026-10-11
Mix2590d
- SEC Filings11(44%)
- Insider9(36%)
- Other4(16%)
- Earnings1(4%)
Latest news
25 items- SECSEC Form 15-12G filed by Barinthus Biotherapeutics plc15-12G - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECSEC Form EFFECT filed by Barinthus Biotherapeutics plcEFFECT - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- INSIDERAmendment: Former 10% owner Oxford Science Enterprises Plc closing all direct ownership in the company (SEC Form 4)4/A - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- SECSEC Form 25 filed by Barinthus Biotherapeutics plc25 - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- INSIDERDirector Scheeren Joseph returned 23,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- INSIDERDirector Phillips Anne M. returned 3,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- INSIDERDirector Wright Robin returned 48,256 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- INSIDERDirector Morgon Pierre A. returned 10,506 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- INSIDERDirector Hammacher Alex returned 3,000 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- INSIDERChief Medical Officer Hooftman Leon was granted 361,530 units of Ordinary Shares and returned 361,530 units of Ordinary Shares to the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- INSIDERChief Executive Officer Enright William returned 1,243,377 units of Ordinary Shares to the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- SECSEC Form S-8 POS filed by Barinthus Biotherapeutics plcS-8 POS - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECSEC Form S-8 POS filed by Barinthus Biotherapeutics plcS-8 POS - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- INSIDERDirector Dawes Karen A returned 1,700 units of Ordinary Shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)
- SECSEC Form S-8 POS filed by Barinthus Biotherapeutics plcS-8 POS - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECSEC Form POS AM filed by Barinthus Biotherapeutics plcPOS AM - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECSEC Form S-8 POS filed by Barinthus Biotherapeutics plcS-8 POS - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECSEC Form S-8 POS filed by Barinthus Biotherapeutics plcS-8 POS - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Financial Statements and Exhibits8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- PRBarinthus Bio Provides Update on Proposed Combination with Clywedog TherapeuticsScheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreementScheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market openTopco common stock expected to commence trading on Nasdaq under the ticker symbol "CLYD" following completion of the proposed combination with Clywedog GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc. ("Clywedog") in an all-stock transaction. Notice of
- SECBarinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- SECSEC Form 10-Q filed by Barinthus Biotherapeutics plc10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)
- PRBarinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate DevelopmentsProposed combination with Clywedog Therapeutics Inc. ("Clywedog") progressing towards closingCompleted enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose ("MAD") expected in the fourth quarter of 2026 GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), today announced its financial results for the quarter ended June 30, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation ("I&I") company focused on developing therapies that promote immune t
BRNS FAQ
5 questionsWhere does BRNS stock trade?
Barinthus Biotherapeutics plc (BRNS) is listed on NASDAQ.What sector and industry is BRNS in?
Barinthus Biotherapeutics plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Barinthus Biotherapeutics plc go public?
Barinthus Biotherapeutics plc (BRNS) completed its IPO in 2021.What companies are similar to BRNS?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BRNS side-by-side with any of them on Quantisnow.How can I track BRNS on Quantisnow?
Quantisnow aggregates Barinthus Biotherapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BRNS to receive live email and push alerts on every new disclosure.